keyword
https://read.qxmd.com/read/39293083/magrolimab-plus-rituximab-with-without-chemotherapy-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma
#1
JOURNAL ARTICLE
Joeseph Maakaron, Adam S Asch, Leslie Popplewell, Graham P Collins, Ian W Flinn, Nilanjan Ghosh, Colm Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Gal Hacohen-Kleiman, Yanan Huo, Yi Zhang, Camille Renard, Sonali M Smith, Ranjana H Advani
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for available salvage therapies have limited options for long-term disease control, necessitating novel treatments. Previously, magrolimab (anti-cluster-of-differentiation-47 antibody) plus rituximab (M+R) demonstrated ability to induce complete responses (CR) in R/R DLBCL. Here we report 3-year follow-up data from this phase 1b/2 study (NCT02953509) assessing long-term safety and efficacy of M+R, and initial safety and efficacy of M+R plus gemcitabine-oxaliplatin (M+R-GemOx), in R/R DLBCL...
September 18, 2024: Blood Advances
https://read.qxmd.com/read/39293067/a-phase-ii-study-of-folfox-combined-with-nab-paclitaxel-in-the-treatment-of-metastatic-or-advanced-unresectable-gastric-gastroesophageal-junction-adenocarcinoma-a-big-ten-cancer-research-consortium-trial
#2
JOURNAL ARTICLE
Marie S Dreyer, Mary Mulcahy, Masha Kocherginsky, Yolande Chen, Howard S Hochster, Pashtoon M Kasi, Sheetal Kircher, Emil Lou, Yangruijue Ma, Nataliya V Uboha, Al B Benson
BACKGROUND: Doublet platinum or taxane-based therapies are the current standard backbone of treatment for advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. Previously used anthracycline-based triplet regimens are no longer used routinely due to toxicity and lack of superior efficacy. We hypothesized that the addition of nab-paclitaxel to FOLFOX (FOLFOX-A) would induce higher efficacy and better tolerability. PATIENTS AND METHODS: Eligible patients with chemotherapy-naïve advanced unresectable HER2-negative gastric or GEJ adenocarcinoma were enrolled in this phase II single-arm trial of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 2400 mg/m2 over 46-48 hours) + nab-paclitaxel (150 mg/m2) every 14 days of a 28-day cycle...
September 18, 2024: Oncologist
https://read.qxmd.com/read/39293029/management-of-iron-overload-lessons-from-transfusion-dependent-hemoglobinopathies
#3
JOURNAL ARTICLE
Thomas D Coates
Prior to the advent of effective iron chelation, death from iron-induced cardiomyopathy and endocrine failure occurred in the second decade in patients with thalassemia major and this experience has driven expectation of poor outcomes and caused anxiety in all disorders associated with iron loading to this day. To be clear, severe iron overload still causes significant morbidity and mortality in many parts of the world, but current understanding of iron metabolism, non-invasive monitoring of organ specific iron loading in humans and effective iron chelators have dramatically reduced morbidity of iron overload...
September 18, 2024: Blood
https://read.qxmd.com/read/39292928/pomalidomide-for-epistaxis-in-hereditary-hemorrhagic-telangiectasia
#4
RANDOMIZED CONTROLLED TRIAL
Hanny Al-Samkari, Raj S Kasthuri, Vivek N Iyer, Allyson M Pishko, Jake E Decker, Clifford R Weiss, Kevin J Whitehead, Miles B Conrad, Marc S Zumberg, Jenny Y Zhou, Joseph Parambil, Derek Marsh, Marianne Clancy, Lauren Bradley, Lisa Wisniewski, Benjamin A Carper, Sonia M Thomas, Keith R McCrae
BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in iron-deficiency anemia and reduced health-related quality of life. METHODS: We conducted a randomized, placebo-controlled trial to evaluate the safety and efficacy of pomalidomide for the treatment of HHT. We randomly assigned patients, in a 2:1 ratio, to receive pomalidomide at a dose of 4 mg daily or matching placebo for 24 weeks...
September 19, 2024: New England Journal of Medicine
https://read.qxmd.com/read/39292913/investing-in-sickle-cell-disease%C3%A2-global-attention-on-and-funding-of-disease-research-would-benefit-millions
#5
JOURNAL ARTICLE
Ambroise Wonkam
No abstract text is available yet for this article.
October 1, 2024: Scientific American
https://read.qxmd.com/read/39292912/ease-the-pain-the-excruciating-pain-of-sickle-cell-disease-is-difficult-to-prevent-or-treat-researchers-are-working-on-new-ways-to-provide-relief
#6
JOURNAL ARTICLE
https://read.qxmd.com/read/39292911/living-with-sickle-cell-disease%C3%A2-as-told-to-roxanne-scott
#7
JOURNAL ARTICLE
Roxanne Scott
No abstract text is available yet for this article.
October 1, 2024: Scientific American
https://read.qxmd.com/read/39292910/new-treatments-for-sickle-cell-disease-after-years-of-little-progress-new-therapies-to-treat-or-even-cure-the-disease-are-reaching-patients
#8
JOURNAL ARTICLE
Sara Reardon
No abstract text is available yet for this article.
October 1, 2024: Scientific American
https://read.qxmd.com/read/39292909/changing-the-story-these-sickle-cell-researchers-and-advocates-are-fighting-for-change-at-every-level-from-the-laboratory-to-the-clinic-to-the-global-stage-and-their-work-is-transforming-lives
#9
JOURNAL ARTICLE
https://read.qxmd.com/read/39292908/reshaping-a-disease-new-therapies-are-changing-the-lives-of-sickle-cell-patients-understanding-their-perspectives-could-improve-all-of-medicine
#10
JOURNAL ARTICLE
Maryn McKenna
No abstract text is available yet for this article.
October 1, 2024: Scientific American
https://read.qxmd.com/read/39292907/new-attention-and-hope-for-sickle-cell-improving-sickle-cell-care-by-expanding-treatment-options-advancing-new-therapies-and-amplifying-the-voices-of-people-with-the-disease
#11
JOURNAL ARTICLE
https://read.qxmd.com/read/39292880/blurred-boundaries-this-month-s-issue-covers-the-reasons-it-s-so-hard-to-go-back-to-the-moon-the-science-of-empathy-and-new-advances-in-treating-sickle-cell-disease
#12
JOURNAL ARTICLE
https://read.qxmd.com/read/39292421/a-cost-utility-analysis-of-ferric-derisomaltose-versus-ferric-carboxymaltose-in-patients-with-iron-deficiency-anemia-in-china
#13
JOURNAL ARTICLE
Fengkui Zhang, Aizong Shen, Waqas Ahmed, Richard F Pollock
INTRODUCTION: Intravenous (IV) iron is the recommended treatment for patients with iron deficiency anemia (IDA) unresponsive to oral iron treatment, in whom oral iron is contraindicated, or where rapid iron replenishment is required. Ferric derisomaltose (FDI) and ferric carboxymaltose (FCM) are high-dose, rapid-infusion, IV iron formulations that have recently been compared in three head-to-head randomized controlled trials (RCTs), which showed significantly higher incidence of hypophosphatemia after administration of FCM than FDI...
September 18, 2024: Advances in Therapy
https://read.qxmd.com/read/39292398/surgical-indication-and-management-of-obstructive-colonic-metastasis-from-primary-lung-adenocarcinoma-report-of-a-case-and-review-of-the-literature
#14
JOURNAL ARTICLE
Mai Watanabe, Shingo Tsujinaka, Tomoya Miura, Yoshihiro Sato, Yoh Kitamura, Kentaro Sawada, Atsushi Mitamura, Hiroto Sakurai, Noriko Kondo, Kazuhiro Takami, Kuniharu Yamamoto, Toru Nakano, Yu Katayose, Naruo Yoshimura, Chikashi Shibata
BACKGROUND: Colonic metastasis from lung cancer is very rare and is typically associated with poor prognosis. Herein, we report the case of a patient who achieved intermediate-term survival using a multimodal treatment approach, including chemotherapy, immunotherapy, radiotherapy, and surgical resection for obstructive colonic metastasis from primary lung adenocarcinoma. CASE PRESENTATION: A woman in her 50s presented with anemia and a positive fecal occult blood test...
September 18, 2024: Surgical Case Reports
https://read.qxmd.com/read/39292391/predictors-of-major-postoperative-complications-in-cytoreductive-surgery-with-or-without-hyperthermic-intraperitoneal-chemotherapy
#15
JOURNAL ARTICLE
Ana Tejedor, Marina Vendrell, Lana Bijelic, Jaume Tur, Marina Bosch, Graciela Martínez-Pallí
PURPOSE: Cytoreductive Surgery (CRS) ± Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is associated with a high incidence of postoperative morbidity. Our aim was to identify independent, potentially actionable perioperative predictors of major complications. METHODS: We reviewed patients who underwent CRS ± HIPEC from June 2020 to January 2022 at a high-volume center. Postoperative complications were categorized using the Comprehensive Complication Index, with the upper quartile defining major complications...
September 18, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/39291322/prevalence-of-anaplasma-spp-and-theileria-spp-antigens-and-antibodies-in-housed-and-grazing-korean-indigenous-cattle
#16
JOURNAL ARTICLE
Ji-Yeong Ku, Youngwoo Jung, Youngjun Kim, Kyoung-Seong Choi, Jinho Park
Background: Infection with tick-borne pathogens (TBPs) causes anemia, jaundice, and growth retardation in cattle. Many studies have conducted antigen (Ag) tests for major TBPs, such as Anaplasma spp. and Theileria spp., in Korean indigenous cattle (KIC); however, few studies have analyzed antibodies (Ab) against these pathogens. Materials and Methods: This study simultaneously tested 15 housed cattle raised indoor for over a year and 67 grazing cattle for Anaplasma spp. and Theileria spp. Ag using polymerase chain reaction analysis and Ab using enzyme-linked immunosorbent assay...
September 18, 2024: Vector Borne and Zoonotic Diseases
https://read.qxmd.com/read/39291304/ternary-structure-of-plasmodium-vivaxn-myristoyltransferase-with-myristoyl-coa-and-inhibitor-imp-0001173
#17
JOURNAL ARTICLE
Cydni Bolling, Alex Mendez, Shane Taylor, Stanley Makumire, Alexandra Reers, Rachael Zigweid, Sandhya Subramanian, David M Dranow, Bart Staker, Thomas E Edwards, Edward W Tate, Andrew S Bell, Peter J Myler, Oluwatoyin A Asojo, Graham Chakafana
Plasmodium vivax is a major cause of malaria, which poses an increased health burden on approximately one third of the world's population due to climate change. Primaquine, the preferred treatment for P. vivax malaria, is contraindicated in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common genetic cause of hemolytic anemia, that affects ∼2.5% of the world's population and ∼8% of the population in areas of the world where P. vivax malaria is endemic. The Seattle Structural Genomics Center for Infectious Disease (SSGCID) conducted a structure-function analysis of P...
October 1, 2024: Acta Crystallographica. Section F, Structural Biology Communications
https://read.qxmd.com/read/39291254/incidence-risk-factors-organism-types-and-outcomes-of-catheter-related-bloodstream-infections-in-hemodialysis-patients
#18
JOURNAL ARTICLE
Adam Bitunguramye, Gerard Nkundimana, Ahmed M Aboubasha, Jules Kabahizi, William Rutikanga, Laetitia Nshimiyimana, Michel G Rafiki
Background Patients undergoing hemodialysis for End-Stage Renal Disease (ESRD) are at risk for Hemodialysis Catheter-Related Bloodstream Infections (CRBSIs). This study evaluates the incidence, risk factors, organism types, and outcomes of CRBSI in adult patients on maintenance hemodialysis at King Faisal Hospital, Rwanda. Methods This was a prospective cohort study of adult patients with end-stage renal disease undergoing hemodialysis via central venous hemodialysis catheters at King Faisal Hospital, Rwanda...
September 2024: Curēus
https://read.qxmd.com/read/39291215/timing-and-modality-of-kidney-replacement-therapy-in-children-and-adolescents
#19
JOURNAL ARTICLE
Julia Thumfart, Steffen Wagner, Marietta Kirchner, Karolis Azukaitis, Aysun K Bayazit, Lukasz Obrycki, Nur Canpolat, Ipek Kaplan Bulut, Ali Duzova, Ali Anarat, Lucie Bessenay, Rukshana Shroff, Dusan Paripovic, Lale Sever, Cengiz Candan, Francesca Lugani, Alev Yilmaz, Fatos Yalcinkaya, Klaus Arbeiter, Aysel Kiyak, Aleksandra Zurowska, Matthias Galiano, Uwe Querfeld, Anette Melk, Franz Schaefer
INTRODUCTION: The choice and timing of kidney replacement therapy (KRT) is influenced by clinical factors, laboratory features, feasibility issues, family preferences, and clinicians' attitudes. We analyzed the factors associated with KRT modality and timing in a multicenter, multinational prospective pediatric cohort study. METHODS: A total of 695 pediatric patients with chronic kidney disease (CKD) enrolled into the Cardiovascular Comorbidity in Children with CKD (4C) study at age 6 to 17 years with estimated glomerular filtration rate (eGFR) of 10 to 60 ml/min per 1...
September 2024: KI Reports
https://read.qxmd.com/read/39290705/expanding-clinical-characteristics-and-genotypic-profiling-of-yao-syndrome-in-chinese-patients
#20
JOURNAL ARTICLE
Jingyuan Zhang, Xin Huang, Min Shen
OBJECTIVES: Yao syndrome (YAOS, OMIM# 617321) is a kind of systemic autoinflammatory diseases (SAIDs) linked to the nucleotide-binding oligomerization domain containing 2 ( NOD2 ). Clinical reports of YAOS in China are sparse. Herein, we reported the largest YAOS cohort of Chinese patients to expand the understanding of its phenotype, genotype, and therapeutic responses. METHODS: This study enrolled 15 adult patients diagnosed with YAOS at Peking Union Medical College Hospital from April 2015 to May 2024...
2024: Frontiers in Immunology
keyword
keyword
329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.